Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children

Malaria Journal

Volumn 8, Issue 1, 2009, Pages

  Katrak, Shereen ^a,b   Gasasira, Anne ^b,c   Arinaitwe, Emmanuel ^c   Kakuru, Abel ^c   Wanzira, Humphrey ^c   Bigira, Victor ^c   Sandison, Taylor G ^d   Homsy, Jaco ^e,f   Tappero, Jordan W ^f   Kamya, Moses R ^g   Dorsey, Grant ^h  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAKERERE UNIVERSITY   (Uganda)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; COTRIMOXAZOLE; DIHYDROARTEMISININ PLUS PIPERAQUINE; DUOCOTECXIN; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMISININ DERIVATIVE; DIHYDROQUINGHAOSU; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; PIPERAQUINE; QUINOLINE DERIVATIVE;

ANEMIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BED NET; BLOOD SMEAR; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; DYSPNEA; FATALITY; FEMALE; GROUPS BY AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; JAUNDICE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALAISE; MALARIA; MALE; OPEN STUDY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RASH; RETREATMENT; RISK FACTOR; SEIZURE; SIDE EFFECT; UGANDA; VOMITING; WEIGHT REDUCTION; DRUG COMBINATION; FOLLOW UP; MALARIA FALCIPARUM; TREATMENT OUTCOME;

ANTIMALARIALS; ARTEMISININS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FLUORENES; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INFANT; LONGITUDINAL STUDIES; MALARIA, FALCIPARUM; MALE; QUINOLINES; RISK FACTORS; TREATMENT OUTCOME; UGANDA;

EID: 72849137417     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-8-272     Document Type: Article

References (27)

1. A major transition in malaria treatment: The adoption and deployment of artemisinin-based combination therapies. A Bosman K Mendis, Am J Trop Med Hyg 2007 77 193 197
2. World Health Organization (WHO), Global AMDP Database-AFRO 2008 http://www.who.int/malaria/amdp/amdp-afro.htm Accessed December 7, 2008
3. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: A randomized trial. MR Kamya A Yeka H Bukirwa M Lugemwa JB Rwakimari SG Staedke AO Talisuna B Greenhouse F Nosten PJ Rosenthal F Wabwire-Mangen G Dorsey, PLoS Clin Trials 2007 2 e20
4. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. C Karema CI Fanello C van Overmeir JP van Geertruyden W van Doren D Ngamije U D'Alessandro, Trans R Soc Trop Med Hyg 2006 100 1105 11 (Pubitemid 44464010)
5. Efficacy and safety of dihydroartemisinin-piperaquine. HY Myint EA Ashley NP Day F Nosten NJ White, Trans R Soc Trop Med Hyg 2007 101 858 66
6. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: A randomized trial to guide policy in Uganda. A Yeka G Dorsey MR Kamya A Talisuna M Lugemwa JB Rwakimari SG Staedke PJ Rosenthal F Wabwire-Mangen H Bukirwa, PLoS ONE 2008 3 e2390
7. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. I Zongo G Dorsey N Rouamba C Dokomajilar Y Sere PJ Rosenthal JB Ouédraogo, Clin Infect Dis 2007 45 1453 61 10.1086/522985 17990228
8. Susceptibility of Plasmodium falciparum to antimalarial drugs: Report on global monitoring 1996-2004. World Health Organization (WHO), Geneva 2005
9. Pharmacovigilance of antimalarial treatment in Africa: Is it possible? AO Talisuna SG Staedke U D'Alessandro, Malar J 2006 5 50
10. Malaria pharmacovigilance in Africa: Lessons from a pilot project in Mpumalanga province, South Africa. U Mehta D Durrheim A Mabuza L Blumberg E Allen KI Barnes, Drug Saf 2007 30 899 910
11. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: Longitudinal randomized trial in HIV-infected and uninfected children. E Arinaitwe TG Sandison H Wanzira A Kakuru J Homsy J Kalamya MR Kamya N Vora B Greenhouse PJ Rosenthal J Tappero G Dorsey, Clin Infect Dis 2009 49 1629 37 10.1086/647946 19877969
12. Variation in malaria transmission intensity in seven sites throughout Uganda. PE Okello W Van Bortel AM Byaruhanga A Correwyn P Roelants A Talisuna U D'Alessandro M Coosemans, Am J Trop Med Hyg 2006 75 219 25
13. Clinical safety data management: Definitions and standards for expedited reporting E2A. International Conference on Harmonisation (ICH). ICH harmonised tripartite guideline, Technical Document, ICH 1994
14. Pediatric toxicity tables. Division of microbiology and infectious diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 2001 http://www3.niaid.nih.gov/NR/rdonlyres/B7B341E5-2F99- 4449-AABA-384B2BAD0E19/0/dmidpedtox.doc Accessed April 10, 2008
15. Monitoring antimalarial safety and tolerability in clinical trials: A case study from Uganda. SG Staedke P Jagannathan A Yeka H Bukirwa K Banek C Maiteki-Sebuguzi TD Clark B Nzarubara D Njama-Meya A Mpimbaza PJ Rosenthal MR Kamya F Wabwire-Mangen G Dorsey AO Talisuna, Malar J 2008 7 107 18547416 10.1186/1475-2875-7-107 (Pubitemid 352000602)
16. An integrated assessment of the clinical safety of artemether- lumefantrine: A new oral fixed-dose combination antimalarial drug. R Bakshi I Hermeling-Fritz I Gathmann E Alteri, Trans R Soc Trop Med Hyg 2000 94 419 24 10.1016/S0035-9203(00)90126-3 11127248
17. Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: A four-arm randomised effectiveness trial. TK Mutabingwa D Anthony A Heller R Hallett J Ahmed C Drakeley BM Greenwood CJ Whitty, Lancet 2005 365 1474 80 10.1016/S0140-6736(05)66417-3 15850631
18. Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. H Bukirwa A Yeka MR Kamya A Talisuna K Banek N Bakyaita JB Rwakimari PJ Rosenthal F Wabwire-Mangen G Dorsey SG Staedke, PLoS Clin Trials 2006 1 e7
19. A randomised trial to assess the safety and efficacy of artemether-lumefantrine (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwanda. CI Fanello C Karema W van Doren C Van Overmeir D Ngamije U D'Alessandro, Trans R Soc Trop Med Hyg 2007 101 344 50 (Pubitemid 46196260)
20. Combination therapy for uncomplicated falciparum malaria in Ugandan children: A randomized trial. G Dorsey S Staedke TD Clark D Njama-Meya B Nzarubara C Maiteki-Sebuguzi C Dokomajilar MR Kamya PJ Rosenthal, JAMA 2007 297 2210 9 10.1001/jama.297.20.2210 17519410
21. Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children. C Maiteki-Sebuguzi P Jagannathan VM Yau TD Clark D Njama-Meya B Nzarubara AO Talisuna MR Kamya PJ Rosenthal G Dorsey SG Staedke, Malar J 2008 7 106
22. Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria. AA Omari C Gamble P Garner, Cochrane Database Syst Rev 2005 4 CD005564
23. An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People's Democratic Republic (Laos). M Mayxay V Thongpraseuth M Khanthavong N Lindegardh M Barends S Keola T Pongvongsa S Phompida R Phetsouvanh K Stepniewska NJ White PN Newton, Trop Med Int Health 2006 11 1157 65 10.1111/j.1365-3156.2006.01671.x 16903879
24. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. J Tarning EA Ashley N Lindegardh K Stepniewska L Phaiphun NP Day R McGready M Ashton F Nosten NJ White, Antimicrob Agents Chemother 2008 52 1052 61 18180343 10.1128/AAC.00955-07
25. Drug interactions involving combination antiretroviral therapy and other anti-infective agents: Repercussions for resource-limited countries. KE Dooley C Flexner AS Andrade, J Infect Dis 2008 198 948 61 10.1086/591459 18713054
26. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. P German S Parikh J Lawrence G Dorsey PJ Rosenthal D Havlir E Charlebois W Hanpithakpong N Lindegardh FT Aweeka, J Acquir Immune Defic Syndr 2009 51 424 9 10.1097/QAI.0b013e3181acb4ff 19506482
27. High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. AF Gasasira MR Kamya J Achan T Mebrahtu JN Kalyango T Ruel E Charlebois SG Staedke A Kekitiinwa PJ Rosenthal D Havlir G Dorsey, Clin Infect Dis 2008 46 985 91 10.1086/529192 18444813